Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

• Autores principales: Vanessa Zhu (Autor), Jürgen Burhenne (Autor), Johanna Weiss (Autor), Mathias Haag (Autor), Ute Hofmann (Autor), Matthias Schwab (Autor), Stephan Urban (Autor), Gerd Mikus (Autor), David Czock (Autor), Walter E. Haefeli (Autor), Antje Blank (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transporting polypeptide 1B1 (OATP1B1) and cytochrome P450...